Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRACK trial: Low Dose Rivaroxaban in Advanced CKD
NCT03969953Phase 3Completed
- Sponsor
- The George Institute for Global Health
- Start
- Jan 2021
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of rivaroxaban in cardiovascular disease (CVD), sponsored by The George Institute for Global Health. Started Jan 2021; status: completed.
02
Drugs
rivaroxaban
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT03969953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03969953.